Paris – 30 March 2015– EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs[1],today celebrated the listing of Cerenis Therapeutics, an international biopharmaceutical company dedicated to discovering and developing innovative HDL (“good cholestrol”) therapies for the treatment of cardiovascular and metabolic disease. Cerenis Therapeutics is listed on the Euronext Paris regulated market in Compartment B.
Founded in Toulouse, Cerenis is a biopharmaceutical company focusing on HDL therapies, one of the most promising therapeutic options for eliminating excess cholesterol and reducing atherosclerotic plaque. Developing one of the most advanced HDL solutions on the market – CER-001 – Cerenis can draw on solid resources to accelerate its product progress in meeting the pressing medical needs of nearly 3 million patients, and is positioned to capture a sizeable share of the market.
Cerenis Therapeutics (ticker symbol: CEREN) was listed through the admission to trading of 17,788,878 ordinary shares making up its equity, including 4,207,316 new shares issued under a Global Offering[2]after full exercise of the extension clause and the over-allotment option.
The Global Placement and Public Offering proved very popular with domestic and international investors, both retail and institutional.
The admission and issue price of Cerenis Therapeutics was set at €12.70 per share, at the high end of the price range. Market capitalisation on the day of listing was €226 million, and the operation raised a total of €53.4 million.
Jean-Louis Dasseux, Founder and CEO of Cerenis Therapeuticssaid:“Our extremely successful listing highlights the enormous potential of HDL therapy, one of the most effective treatments for cardiovascular disease. Investors’ enthusiasm also reflects CER-001’s position as frontrunner, with its development lead underpinned by a satisfactory safety and effectiveness profile, along with a proven mass production process. This new step in our business strategy positions us to better achieve our innovative drive to combat this 21st century plague more effectively. We are aware of the stakes and grateful to our shareholders, past and new, for their trust. And we would like to extend sincere thanks – bothto them and to our employees, who have played an essential role throughout our growth.”
Eric Forest, Chairman and CEO of EnterNext, said“We congratulate Cerenis Therapeutics on the largest round of equity finance raised by a French biotech company on Euronext Paris since 2000. The success and size of yet another listing of a company from southwestern France testifies once again to the region’s potential. Funds raised will allow Cerenis Therapeutics to step up deployment of its innovation-driven growth strategy.”